Tsagalis George, Psimenou Erasmia, Iliadis Athanasios, Nakopoulou Lydia, Laggouranis Antonios
Renal Unit, Alexandra Hospital, Athens, Greece.
Am J Kidney Dis. 2009 Aug;54(2):340-4. doi: 10.1053/j.ajkd.2008.12.024. Epub 2009 Mar 21.
Corticosteroids and/or cyclosporine constitute the present therapeutic approach for patients with focal segmental glomerulosclerosis (FSGS). The high incidence of side effects for the former and risk of nephrotoxicity combined with the high relapse rate after discontinuation for the latter render their use problematic. Results concerning the role of rapamycin in the treatment of patients with FSGS are conflicting. We describe results for 3 patients treated with a combination of low-dose steroids and rapamycin for FSGS, focusing on the importance of maintaining low drug (rapamycin) levels by using a twice-daily regimen.
